Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Show more
Location: 201 Haskins Way, South San Francisco, CA, 94080, United States | Website: https://www.lyell.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
144.4M
52 Wk Range
$7.65 - $38.40
Previous Close
$9.75
Open
$9.71
Volume
19,243
Day Range
$9.58 - $9.83
Enterprise Value
-113.5M
Cash
301.2M
Avg Qtr Burn
-43.78M
Insider Ownership
11.77%
Institutional Own.
63.64%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LYL314 Details B-cell lymphoma | Phase 1/2 Data readout | |
LYL119 Details Solid tumor/s, Cancer | Failed Discontinued | |
LYL797 Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Breast cancer | Failed Discontinued | |
LYL845 Details Solid tumor/s, Cancer, Colorectal cancer , Non-small cell lung carcinoma, Melanoma | Failed Discontinued |